Transition to KPL-387 Monotherapy Dosing & Administration Study

Study Summary

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.

Conditions

Recurrent Pericarditis Heart Diseases Pericarditis

Interventions / Drugs

KPL-387

View on ClinicalTrials.gov ↗

Sponsor

KNSA

Kiniksa Pharmaceuticals

Rare Disease

D37/100

Study Details

Enrollment80 participants

Primary Completion—

Lead SponsorKiniksa Pharmaceuticals International, plc

Data Retrieved2026-04-11 04:18:52.793660+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.